VYNE Therapeutics (VYNE) Competitors $1.46 +0.12 (+8.96%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.45 -0.01 (-0.96%) As of 07/25/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. PYXS, BMEA, INCR, PMVP, GNTA, QNTM, TELO, CUE, AVTX, and IRDShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), PMV Pharmaceuticals (PMVP), Genenta Science (GNTA), Quantum Biopharma (QNTM), Telomir Pharmaceuticals (TELO), Cue Biopharma (CUE), Avalo Therapeutics (AVTX), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Its Competitors Pyxis Oncology Biomea Fusion InterCure PMV Pharmaceuticals Genenta Science Quantum Biopharma Telomir Pharmaceuticals Cue Biopharma Avalo Therapeutics Opus Genetics Pyxis Oncology (NASDAQ:PYXS) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation. Does the media favor PYXS or VYNE? In the previous week, Pyxis Oncology had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.87 beat Pyxis Oncology's score of 1.82 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Pyxis Oncology Very Positive VYNE Therapeutics Very Positive Which has more risk & volatility, PYXS or VYNE? Pyxis Oncology has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Do institutionals and insiders believe in PYXS or VYNE? 39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 10.6% of Pyxis Oncology shares are owned by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings and valuation, PYXS or VYNE? VYNE Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M4.79-$77.33M-$1.59-0.79VYNE Therapeutics$605K36.71-$39.83M-$0.99-1.47 Do analysts rate PYXS or VYNE? Pyxis Oncology presently has a consensus target price of $9.00, indicating a potential upside of 620.00%. VYNE Therapeutics has a consensus target price of $6.25, indicating a potential upside of 328.08%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than VYNE Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PYXS or VYNE more profitable? Pyxis Oncology has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. Pyxis Oncology's return on equity of -57.49% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -57.49% -45.17% VYNE Therapeutics -6,974.55%-71.89%-58.94% SummaryPyxis Oncology beats VYNE Therapeutics on 9 of the 16 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.38M$2.50B$5.70B$9.50BDividend YieldN/A1.75%4.60%4.01%P/E Ratio-1.479.0528.1020.05Price / Sales36.71592.30429.3789.38Price / CashN/A165.2136.2258.56Price / Book0.415.168.665.87Net Income-$39.83M$30.99M$3.25B$258.55M7 Day Performance25.86%7.74%4.22%3.73%1 Month Performance-9.88%16.27%10.51%11.75%1 Year Performance-30.14%-1.88%34.40%18.03% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.9491 of 5 stars$1.46+9.0%$6.25+328.1%-30.5%$20.38M$605K-1.4730Positive NewsPYXSPyxis Oncology2.4244 of 5 stars$1.13flat$9.00+696.5%-67.5%$70M$16.15M-0.7160BMEABiomea Fusion3.2788 of 5 stars$1.83-1.1%$20.10+998.4%-66.5%$69.51MN/A-0.5250Upcoming EarningsINCRInterCure0.6609 of 5 stars$1.55+2.0%N/A-36.3%$69.27M$66.28M0.00350Positive NewsPMVPPMV Pharmaceuticals3.1648 of 5 stars$1.34+0.8%$5.50+310.4%-14.5%$69.10MN/A-1.1450News CoverageGNTAGenenta Science2.7341 of 5 stars$3.77-0.1%$25.00+564.0%-9.5%$68.95MN/A0.007QNTMQuantum BiopharmaN/A$23.71+1.5%N/AN/A$67.95MN/A-1.48N/ATELOTelomir Pharmaceuticals2.9219 of 5 stars$2.21-3.1%$15.00+578.7%-44.8%$67.86MN/A-5.261News CoverageGap DownHigh Trading VolumeCUECue Biopharma4.0437 of 5 stars$0.88-1.9%$3.00+239.8%+25.5%$67.82M$9.29M-1.3260Positive NewsAVTXAvalo Therapeutics3.5396 of 5 stars$6.73+7.7%$30.00+345.8%-42.5%$67.67M$440K0.0040News CoveragePositive NewsIRDOpus Genetics1.6456 of 5 stars$1.19+5.3%$7.33+516.2%N/A$67.42M$13.65M-0.5714 Related Companies and Tools Related Companies PYXS Competitors BMEA Competitors INCR Competitors PMVP Competitors GNTA Competitors QNTM Competitors TELO Competitors CUE Competitors AVTX Competitors IRD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
